End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
86.74 CNY | -2.00% | -3.05% | -35.88% |
Sales 2023 * | 6,951 M 952 M | Sales 2024 * | 9,280 M 1,271 M | Capitalization | 41 781 M 5 723 M |
---|---|---|---|---|---|
Net income 2023 * | 1,028 M 141 M | Net income 2024 * | 1,386 M 190 M | EV / Sales 2023 * | 5,83x |
Net cash position 2023 * | 1,284 M 176 M | Net cash position 2024 * | 1,477 M 202 M | EV / Sales 2024 * | 4,34x |
P/E ratio 2023 * | 40,6x | P/E ratio 2024 * | 29,2x | Employees | - |
Yield 2023 * | 0,68% | Yield 2024 * | 0,96% | Free-Float | 30.01% |
More Fundamentals
* Assessed data
More news
More news
1 day | -2.00% | ||
1 week | -3.05% | ||
1 month | -6.60% | ||
3 months | -2.71% | ||
6 months | -23.51% | ||
Current year | -35.88% |
1 week
86.26
89.48

1 month
86.26
94.45

Current year
84.99
136.40

1 year
84.99
139.36

3 years
84.99
314.99

5 years
72.00
314.99

10 years
72.00
314.99

Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.84% | 1 M$ | -16.01% | - | |
0.74% | 3 M$ | -16.76% | - | |
0.39% | 1 M$ | -10.62% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-09-28 | 86.74 | -2.00% | 1,619,374 |
23-09-27 | 88.51 | +0.77% | 1,140,615 |
23-09-26 | 87.83 | -1.83% | 1,354,856 |
End-of-day quote Shanghai Stock Exchange, September 27, 2023
More quotes
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED is a China-based company mainly engaged in the research, development, production and sales of various raw materials of sodium hyaluronate and relevant bioactive ingredients, as well as end products such as medicines, medical devices and functional skin care products. The Company relies on microbial fermentation and cross-linking technology platforms to provide raw materials such as gradesodium hyaluronate, medical end products such as sodium hyaluronate injection and functional skin care products to serve the world in areas like pharmaceutical, cosmetic and food manufacturing, medical institutions and users. The Company owns cosmetics brands such as BIOHYALUX, CYTOCARE and MEDREPAIR. The Company conducts its businesses within the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2023-10-26
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy

Mean consensus
BUY
Number of Analysts
20
Last Close Price
86.74CNY
Average target price
108.80CNY
Spread / Average Target
+25.43%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-35.88% | 5 726 M $ | |
+51.12% | 65 M $ | |
+78.04% | 2 618 M $ | |
-58.44% | 267 M $ | |
+80.97% | 958 M $ | |
-.--% | 1 365 M $ | |
-18.18% | 1 054 M $ | |
-23.73% | 24 780 M $ | |
+4.77% | 153 M $ | |
-2.56% | 52 M $ |